Calcium channel blockers and the risk of cancer

JAMA

Volumn 279, Issue 13, 1998, Pages 1000-1004

  Rosenberg, Lynn ^a   Rao, R Sowmya ^a   Palmer, Julie R ^a   Strom, Brian L ^b   Stolley, Paul D ^c   Zauber, Ann G ^d   Warshauer, M Ellen ^e   Shapiro, Samuel ^a  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; DATA ANALYSIS; DRUG EXPOSURE; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTENSION; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032054681     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.13.1000     Document Type: Article

References (31)

1. Pahor M, Guralnik JM, Corti M-C, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493-497.
2. Pahor M, Guralnik JM, Salive ME, Corti M-C, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 1996; 9:695-699.
3. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium channel blockers and risk of cancer. Lancet. 1997;349:525-528.
4. Olsen JH, Toft Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension. 1997;29:1091-1094.
5. Fitzpatrick AL, Daling JR, Furberg CD, Krommal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80:1438-1447.
6. Shapiro S. Case control surveillance. In: Strom BL, ed. Pharmacoepidemiology. 2nd ed. Chichester, England: John Wiley & Sons Inc; 1994:301-322.
7. Schlesselman JJ. Case-Control Studies: Design, Conduct, Analysis. New York, NY: Oxford Universitv Press; 1982.
8. McLanghlin JK, Mandel JS, Blot WJ, et al. A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst. 1984;72:275-284.
9. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst. 1986;77:351-356.
10. Asal NR, Geyer JR, Risser DR, et al. Risk factors in renal cell carcinoma, II: medical history, occupations, multivariate analysis, and conclusions. Cancer Detect Prev. 1988;13:263-279.
11. Mellemgaard A, Moller H, Olsen JH. Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control. 1992;3:309-312.
12. McCredie M, Stewart JH. Risk factors for kidney cancer in New-South-Wales, Australia, II: urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control. 1992;3:323-331.
13. Lindblad P, McLaughlin JK, Mellemgaard A, Adami H-O. Risk of kidney cancer among patients using analgesics and diuretics: a population-based cohort study. Int J Cancer. 1993;55:5-9.
14. Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993;4:101-110.
15. Finkle WD, McLaughlin JK, Rasgon SA, Yeoh HH, Low JE. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control. 1993;4:55-58.
16. Hiatt RA, Tolan K, Quesenberry CP Jr. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control. 1994;5:319-325.
17. McLaughlin JK, Chow WH, Mandel JS, et al. International renal-cell cancer study, VIII: role of diuretics, other anti-hypertensive medications, and hypertension. Int J Cancer. 1995;63:216-221.
18. Heath CW Jr, Lally CA, Calle EE, McLaughlin JK, Thun MJ. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol. 1997;145:607-613.
19. Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology. 1997;8:31-36.
20. Connor J, Sawczuk IS, Benson MC, et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate. 1988;13:119-130.
21. 2+ channels exposed to serum from patients with type I diabetes. Science. 1993;261:86-90.
22. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J. 1993;7:453-463.
23. Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens. 1996;9:713-714.
24. 2+ in toxic cell killing. Trends Pharmacol Sci. 1989;10:281-285.
25. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
26. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet. 1993;341:1251-1254.
27. Sen S. Programmed cell death: concept mechanism and control. Biol Rev. 1992;67:287-319.
28. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell. 1993; 74:777-779.
29. Tenniswood MP, Guenette RS, Lakins J, Mooibroek M, Wongg P, Welsh JE. Active cell death (ACD) in hormone-dependent tissues. Cancer Metastasis Rev. 1992;11:197-200.
30. Balakumaran A, Campbell GA, Mosler MT. Calcium channel blockers induce thymic apoptosis in vivo in rats. Toxicol Appl Pharmacol. 1996;139:122-127.
31. Wyllie AH. Apoptosis (The 1992 Frank Rose Memorial Lecture). Br J Cancer. 1993;67:205-208.